Interferon Patents (Class 424/85.4)
-
Patent number: 10046029Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.Type: GrantFiled: December 10, 2013Date of Patent: August 14, 2018Inventor: Martin Roecken
-
Patent number: 9956191Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.Type: GrantFiled: March 7, 2017Date of Patent: May 1, 2018Inventors: Ching-Ping Tseng, Pei-Wen Hsieh, Yao-Wen Chang
-
Patent number: 9944686Abstract: This invention provides a method for treating tumors in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1, wherein the tumors are selected from the group consisting of skin cancer, basal cell carcinoma, liver cancer, thyroid cancer, rhinopharyngeal cancer, solid carcinoma, prostate cancer, esophageal cancer, pancreatic cancer, superficial bladder cancer, hemangioma, epidermoid carcinoma, cervical cancer, glioma, leucocythemia, acute leucocythemia, chronic leucocythemia, lymphadenoma, and polycythemia vera.Type: GrantFiled: September 5, 2013Date of Patent: April 17, 2018Assignee: SUPERLAB FAR EAST LIMITEDInventor: Guangwen Wei
-
Patent number: 9868727Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: July 23, 2015Date of Patent: January 16, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Sung-Sau So, Anthony K. Ogawa, Rongze Kuang, Heping Wu, Amjad Ali, Ying-Duo Gao, Yu Jiang, Chunsing Li, Tingting Yu
-
Patent number: 9861574Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.Type: GrantFiled: April 9, 2014Date of Patent: January 9, 2018Assignee: Duke UniversityInventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
-
Patent number: 9827213Abstract: Provided are an astragalus membranaceus fermentation product and a method of producing the astragalus membranaceus fermentation product, in which a lactic acid bacteria starter or a yeast starter proliferated and cultured in a medium is inoculated into a mixture, in which astragalus membranaceus, sugar, and water are mixed, to be fermented, and then a pH of a fermentation material obtained by fermenting is measured, and the fermentation material having a pH within a predetermined range is filtered and dried to obtain the astragalus membranaceus fermentation product.Type: GrantFiled: November 24, 2015Date of Patent: November 28, 2017Assignee: COSISBIO CO., LTD.Inventors: Terry Cho Hyun, Sang-hurn Park, Dong-goo Kim, Ji-young Shin
-
Patent number: 9820972Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.Type: GrantFiled: January 20, 2016Date of Patent: November 21, 2017Assignee: AB PHARMA LTD.Inventor: Zheng-Yun James Zhan
-
Patent number: 9783589Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell.Type: GrantFiled: August 13, 2013Date of Patent: October 10, 2017Assignee: IMMUNGENE INCInventors: Iqbal Grewal, Sanjay Khare, Michael Gresser
-
Patent number: 9763923Abstract: Provided is a method of reducing senescence in a cell or subject, or treating or preventing a symptom or disease associated therewith, by administering a BRAF inhibitor to the cell or subject.Type: GrantFiled: May 2, 2016Date of Patent: September 19, 2017Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jungwon Keum, Joontae Park, Chulwon Jung, Sangchul Park, Youngsam Lee
-
Patent number: 9718782Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.Type: GrantFiled: September 17, 2014Date of Patent: August 1, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
-
Patent number: 9707215Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.Type: GrantFiled: June 20, 2013Date of Patent: July 18, 2017Assignee: COCRYSTAL, DISCOVERY, INC.Inventors: Sam Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson
-
Patent number: 9695224Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: GrantFiled: February 9, 2016Date of Patent: July 4, 2017Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 9682100Abstract: Antiviral cationic polyamines were prepared by modifying polyethylenimines with N-acylating agents that introduce a side chain comprising one or more carbons and at least one alcohol hydroxy group. The cationic polyamines can have a linear or branched polyethylenimine backbone structure. Preferably, the cationic polyamines comprise pendant monosaccharide groups, which can be introduced via a cyclic carbonate comprising a pendant protected monosaccharide (e.g., mannose) group. The cationic polyamines can be active and selective against a broad spectrum of viruses at low concentrations, and are generally non-toxic.Type: GrantFiled: January 26, 2015Date of Patent: June 20, 2017Assignees: International Business Machines Corporation, Agency For Science, Technology And Research, National University of SingaporeInventors: James L. Hedrick, Ichiyama Koji, Naoki Yamamoto, Chuan Yang, Yi Yan Yang
-
Patent number: 9623022Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogType: GrantFiled: April 25, 2016Date of Patent: April 18, 2017Assignees: Janssen Sciences Ireland UC, Medivir ABInventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Abdellah Tahri, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Vladimir Ivanov, Mikael Pelcman, Anna Karin Belfrage, Per-Ola Mikael Johansson, Sandrine Marie Helene Vendeville
-
Patent number: 9616058Abstract: The present invention relates to the use of potent selective LSD inhibitors and LSD/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency.Type: GrantFiled: February 24, 2011Date of Patent: April 11, 2017Assignee: Oryzon Genomics, S.A.Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Muñoz, Nathalie Guibourt, Jonathan Alleman Baker
-
Patent number: 9598433Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: October 31, 2013Date of Patent: March 21, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
-
Patent number: 9593108Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.Type: GrantFiled: April 5, 2010Date of Patent: March 14, 2017Assignee: PTC Therapeutics, Inc.Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
-
Patent number: 9579391Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.Type: GrantFiled: June 4, 2015Date of Patent: February 28, 2017Assignee: SmartCells, Inc.Inventors: Todd C. Zion, Thomas M. Lancaster
-
Patent number: 9573978Abstract: The present invention relates to a compound of the formula (I), (II), (III), (IV), (V), or (VI) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.Type: GrantFiled: August 12, 2011Date of Patent: February 21, 2017Assignee: S&T GLOBAL, INC.Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
-
Patent number: 9534057Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.Type: GrantFiled: February 2, 2015Date of Patent: January 3, 2017Assignee: IMMUNGENE INCInventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
-
Patent number: 9511059Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.Type: GrantFiled: August 17, 2015Date of Patent: December 6, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Joseph Anthony Bilotta, Zhi Chen, Qingjie Ding, Shawn David Erickson, Eric Mertz, Robert James Weikert
-
Patent number: 9511056Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: May 16, 2014Date of Patent: December 6, 2016Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Patent number: 9486502Abstract: Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.Type: GrantFiled: April 14, 2014Date of Patent: November 8, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rong Li, Sheldon S. Miller, Arvydas Maminishkis
-
Patent number: 9453051Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.Type: GrantFiled: August 29, 2012Date of Patent: September 27, 2016Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbHInventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
-
Patent number: 9428491Abstract: The present invention relates to novel antiviral active 5-{4-[1H-imidazol-5-ylaryl(or hetaryl)]-buta-1,3-diynyl}-1H-imidazoles of the general formula 1 and pharmaceutically acceptable salt thereof, pharmaceutical composition, antiviral medicament, therapeutic kit for prophylaxis and treatment of hepatisis C virus diseases, and method for prophylaxis and treatment of hepatisis C. wherein: R1 and R2—represent optionally identical radicals selected from 2.1 and 2.2, where an asterisk (*) denotes the position of attachment to the imidazole fragment, (S) and (R) are types of chiral centers; R3 is isopropyl or phenyl radicals; Ar an aromatic or heteroaromatic diradical.Type: GrantFiled: November 28, 2011Date of Patent: August 30, 2016Inventors: Alexandre Vasilievich Ivachtchenko, Vadim Vasilievich Bichko, Oleg Dmitrievich Mitkin
-
Patent number: 9402831Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.Type: GrantFiled: November 14, 2012Date of Patent: August 2, 2016Assignee: Synta Pharmaceutical Corp.Inventors: David Proia, Jaime Acquaviva
-
Patent number: 9334291Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.Type: GrantFiled: June 6, 2014Date of Patent: May 10, 2016Assignee: AB PHARMA LTD.Inventor: Zheng-Yun James Zhan
-
Patent number: 9296778Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 21, 2013Date of Patent: March 29, 2016Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et TechniquesInventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
-
Patent number: 9283280Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.Type: GrantFiled: May 13, 2013Date of Patent: March 15, 2016Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Patent number: 9200024Abstract: A methodology for polymer grafting by a polysaccharide synthase allows the creation of a variety of glycosaminoglycan oligosaccharides that have a natural, chimeric, hybrid and/or unnatural sugar structure and/or a targeted size (i.e., substantially monodisperse in size).Type: GrantFiled: December 14, 2011Date of Patent: December 1, 2015Assignee: The Board of Regents of the University of OklahomaInventors: Paul L. DeAngelis, Alison Sismey-Ragatz
-
Patent number: 9198907Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.Type: GrantFiled: April 5, 2010Date of Patent: December 1, 2015Assignee: PTC Therapeutics, Inc.Inventors: Frederick C. Lahser, Zhengxian Gu
-
Patent number: 9193740Abstract: The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: October 19, 2010Date of Patent: November 24, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
-
Patent number: 9139570Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.Type: GrantFiled: January 20, 2015Date of Patent: September 22, 2015Assignee: GILEAD PHARMASSET LLCInventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
-
Patent number: 9133170Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: December 13, 2012Date of Patent: September 15, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: John A. Brinkman, Ramakanth Sarabu, Sung-Sau So
-
Patent number: 9101539Abstract: Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.Type: GrantFiled: May 14, 2010Date of Patent: August 11, 2015Assignee: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.Inventors: Ryoichi Nagata, Shunji Haruta
-
Patent number: 9045463Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R* have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in the treatment or prophylaxis of HCV.Type: GrantFiled: August 6, 2010Date of Patent: June 2, 2015Assignee: Janssen R&D IrelandInventors: David McGowan, Samuel Dominique Demin, Stefaan Julien Last, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20150139944Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.Type: ApplicationFiled: October 23, 2014Publication date: May 21, 2015Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
-
Publication number: 20150139946Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.Type: ApplicationFiled: October 19, 2014Publication date: May 21, 2015Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
-
Patent number: 9034310Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.Type: GrantFiled: February 20, 2003Date of Patent: May 19, 2015Inventor: Stephen B. Cantrell
-
Publication number: 20150132258Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: ApplicationFiled: November 14, 2014Publication date: May 14, 2015Inventor: George D. Hartman
-
Publication number: 20150132260Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: ApplicationFiled: April 19, 2013Publication date: May 14, 2015Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Publication number: 20150125422Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
-
Publication number: 20150125518Abstract: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.Type: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: JOHN R. LAU, W. BLAIR GEHO
-
Publication number: 20150125384Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.Type: ApplicationFiled: November 10, 2014Publication date: May 7, 2015Inventors: Ira S. Mellman, Tarek M. Fahmy, William Mark Saltzman, Michael J. Caplan
-
Publication number: 20150118185Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Inventor: Paul L. DeAngelis
-
Patent number: 9011833Abstract: The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.Type: GrantFiled: October 7, 2011Date of Patent: April 21, 2015Assignee: Novartis AGInventors: Sudhakar Devidasrao Garad, Anasuya Ashok Ghosh, Jay Parthiban Lakshman, Lipa Shah, Radha Vippagunta
-
Patent number: 9005599Abstract: The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.Type: GrantFiled: April 20, 2009Date of Patent: April 14, 2015Assignee: Tissue Regeneration Therapeutics Inc.Inventors: Jane Elizabeth Ennis, Jeffrey Donald Turner, John Edward Davies
-
Publication number: 20150093358Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.Type: ApplicationFiled: November 26, 2014Publication date: April 2, 2015Inventors: FUAD FARES, UDI EYAL FIMA
-
Patent number: 8993266Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: December 20, 2012Date of Patent: March 31, 2015Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
-
Patent number: 8992905Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.Type: GrantFiled: January 12, 2007Date of Patent: March 31, 2015Assignees: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara